In vitro inhibitory effect of luotonin A on human CYP1A

Archives of Pharmacal Research

Volumn 35, Issue 12, 2012, Pages 2199-2203

  Jahng, Yurngdong ^a   Kwon, Oh Kwang ^b   Lee, Sangkyu ^b  

^a Yeungnam University   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

CYP1A1; CYP1A2; Human liver microsomes; In vitro; Inhibition; Luotonin A

Indexed keywords

ALKALOID DERIVATIVE; COMPLEMENTARY DNA; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; ISOPROTEIN; LUOTONIN A; PHENACETIN O DEETHYLASE; RECOMBINANT DNA; UNCLASSIFIED DRUG;

ARTICLE; COMPETITIVE INHIBITION; DRUG INHIBITION; DRUG INTERACTION; DRUG SELECTIVITY; ENZYME MECHANISM; GENE EXPRESSION; GENE PROBE; HUMAN; HUMAN CELL; IN VITRO STUDY; KINETICS; LIVER; MICROSOME;

CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; PYRROLES; QUINONES;

EID: 84875692768     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-1218-0     Document Type: Article

References (17)

1. Bowman, W. R.; Elsegood, M. R.; Stein, T.; and Weaver, G. W.; Radical reactions with 3H-quinazolin-4-ones: synthesis of deoxyvasicinone, mackinazolinone, luotonin A, rutaecarpine and tryptanthrin. Org. Biomol. Chem.; 5, 103-113 (2007). (Pubitemid 44927107)
2. Brüggemann, S. K.; Pfäffle, S.; Peters, S. O.; and Wagner, T.; Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients. Drug Metab. Dispos.; 35, 1721-1724 (2007). (Pubitemid 47481595)
3. Cagir, A.; Jones, S. H.; Gao, R.; Eisenhauer, B. M.; and Hecht, S. M.; Luotonin A. A naturally occurring human DNA topoisomerase I poison. J. Am. Chem. Soc.; 125, 13628-13629 (2003). (Pubitemid 37386014)
4. Chang, T. K.; Chen, J.; and Lee, W. B.; Differential inhibition and inactivation of human CYP1 enzymes by transresveratrol: evidence for mechanism-based inactivation of CYP1A2. J. Pharmacol. Exp. Ther.; 299, 874-882 (2001). (Pubitemid 33104954)
5. Chen, Y.; Tang, Y.; Robbins, G. T.; and Nie, D.; Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor. J. Pharmacol. Exp. Ther.; 334, 999-1008 (2010).
6. FDA, Guidance for Industry Drug interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling. Available at: http://www.fda.gov/cder//guidance (2006).
7. Floreani, M.; Gabbia, D.; Barbierato, M.; De Martin, S.; Palatini, P.; Differential inducing effect of benzo[a]pyrene on gene expression and enzyme activity of cytochromes P450 1A1 and 1A2 in Sprague-Dawley and Wistar rats. Drug Metab. Pharmacokinet.; Epub ahead of print (2012).
8. Guengerich, F. P.; Role of cytochrome P450 enzymes in drugdrug interactions. Adv. Pharmacol.; 43, 7-35 (1997).
9. Hanioka, N.; Ozawa, S.; Jinno, H.; Tanaka-Kagawa, T.; Nishimura, T.; Ando, M.; and Sawada, Ji, J.; Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metab. Dispos.; 30, 391-396 (2002). (Pubitemid 34263823)
10. Jahng, K. C.; Kim, S. I.; Kim, D. H.; Seo, C. S.; Son, J. K.; Lee, S. H.; Lee, E. S.; and Jahng, Y.; One-pot synthesis of simple alkaloids: 2,3-polymethylene-4(3H)-quinazolinones, luotonin A, tryptanthrin, and rutaecarpine. Chem. Pharm Bull. (Tokyo), 56, 607-609 (2008). (Pubitemid 351520155)
11. Liang, J. L.; Cha, H. C.; and Jahng, Y.; Recent advances in the studies on luotonins. Molecules, 16, 4861-4883 (2011).
12. Ma, Z. Z.; Hano, Y. S.; Nomura, T.; and Chen, Y. J.; Novel quinazoline-quinoline alkaloids with cytotoxic and DNA topoisomerase II inhibitory activities. Bioorg. Med. Chem. Lett.; 14, 1193-1196 (2004). (Pubitemid 38229854)
13. Mussardo, P.; Corda, E.; Gonzalez-Ruiz, V.; Rajesh, J.; Girotti, S.; Martin, M. A.; and Olives, A. I.; Study of non-covalent interactions of luotonin A derivatives and the DNA minor groove as a first step in the study of their analytical potential as DNA probes. Anal. Bioanal. Chem.; 400, 321-327 (2011).
14. Nacro, K.; Zha, C. C.; Guzzo, P. R.; Jason Herr, R.; Peace, D.; and Friedrich, T. D.; Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives. Bioorg. Med. Chem.; 15, 4237-4246 (2007). (Pubitemid 46678837)
15. Rochat, B.; Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin. Pharmacokinet.; 44, 349-366 (2005). (Pubitemid 40663682)
16. Voll, M. L.; Yap, K. D.; Terpstra, W. E.; and Crul, M.; Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs. Pharm. World Sci.; 32, 575-580 (2010).
17. Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmer, K. H.; McPhail, A. T.; and Sim, G. A.; Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminate. J. Am. Chem. Soc.; 88, 3888-3890 (1966).